C5 and cold agglutinin disease: This group included 10 patients on complement inhibitors: 7 paroxysmal nocturnal hemoglobinuria on C5 inhibitor eculizumab/ravulizumab (N = 6) or on oral factor B inhibitor (N = 1), and 3 cold agglutinin disease on C1s inhibitor sutimlimab.